Despite the essential roles of sphingolipids both as structural components of membranes and critical signalling molecules, we have a limited understanding of how cells sense and regulate their levels. Here we reveal the function in sphingolipid metabolism of the ORM genes (known as ORMDL genes in humans)-a conserved gene family that includes ORMDL3, which has recently been identified as a potential risk factor for childhood asthma. Starting from an unbiased functional genomic approach in Saccharomyces cerevisiae, we identify Orm proteins as negative regulators of sphingolipid synthesis that form a conserved complex with serine palmitoyltransferase, the first and rate-limiting enzyme in sphingolipid production. We also define a regulatory pathway in which phosphorylation of Orm proteins relieves their inhibitory activity when sphingolipid production is disrupted. Changes in ORM gene expression or mutations to their phosphorylation sites cause dysregulation of sphingolipid metabolism. Our work identifies the Orm proteins as critical mediators of sphingolipid homeostasis and raises the possibility that sphingolipid misregulation contributes to the development of childhood asthma.
Despite the essential roles of sphingolipids both as structural components of membranes and critical signalling molecules, we have a limited understanding of how cells sense and regulate their levels. Here we reveal the function in sphingolipid metabolism of the ORM genes (known as ORMDL genes in humans)-a conserved gene family that includes ORMDL3, which has recently been identified as a potential risk factor for childhood asthma. Starting from an unbiased functional genomic approach in Saccharomyces cerevisiae, we identify Orm proteins as negative regulators of sphingolipid synthesis that form a conserved complex with serine palmitoyltransferase, the first and rate-limiting enzyme in sphingolipid production. We also define a regulatory pathway in which phosphorylation of Orm proteins relieves their inhibitory activity when sphingolipid production is disrupted. Changes in ORM gene expression or mutations to their phosphorylation sites cause dysregulation of sphingolipid metabolism. Our work identifies the Orm proteins as critical mediators of sphingolipid homeostasis and raises the possibility that sphingolipid misregulation contributes to the development of childhood asthma.
As cells grow, divide and respond to their environment, they must synthesize lipids to meet metabolic demands while ensuring the correct balance of a wide array of structurally and functionally diverse lipid species. At the same time, cells need to maintain the correct distribution of lipids within the membrane bilayers of different organelles and the plasma membrane. Regulatory mechanisms that ensure proper levels of some lipid species including sterols 1-3 and various glycerolipids [4] [5] [6] have been identified, with loss of such controls leading to a variety of disease states 1, 7 . Although remarkable progress has been made in defining the protein machinery responsible for synthesizing 8, 9 and transporting sphingolipids [10] [11] [12] [13] , insights into how cells sense and maintain their levels are only now emerging 14, 15 . The need for precise regulation of sphingolipids may be particularly acute as, in addition to the structural roles of the terminal products, several biosynthetic intermediates-including sphingosine, ceramide and their phosphorylated derivates-are signalling molecules that participate in key physiological and pathological processes 16, 17 .
Our investigations into how cells achieve sphingolipid homeostasis stem from analysis of the ORM (or ORMDL) genes, which have been implicated recently in asthma. Asthma has emerged as a major health problem, with rates of childhood disease increasing markedly over the past three decades 18 . There is a strong heritable component that modulates susceptibility to asthma, and many studies have been undertaken to identify genetic risk factors 19 . A breakthrough in these efforts came with a recent genome-wide association study 20 , which identified single nucleotide polymorphisms at chromosome 17q21 near the ORMDL3 gene that confer an increased risk of childhood asthma. Subsequent studies have reproduced this finding in multiple ethnic groups [21] [22] [23] . Furthermore, the disease-associated polymorphisms have been shown to modulate expression of ORMDL3 and the adjacent gene GSDMB 20,24 , suggesting that dysregulation of one or both of these genes may contribute to childhood asthma. Thus genetic variants near ORMDL3 are a widespread risk factor for developing childhood asthma that may raise the incidence of the disease by up to approximately 20% (refs 22, 25) . However, translating these findings into an increased understanding of how ORMDL3 may contribute to the pathogenesis of asthma has been hampered by the lack of information on the function of ORM-family genes.
Members of the ORM gene family encode transmembrane proteins localized in the endoplasmic reticulum (ER) and include two genes in the budding yeast S. cerevisiae (ORM1/2) and three genes in humans (ORMDL1/2/3) 26 . The Orm proteins have no known functional domains, and little is known about their cellular role; however, they are strongly conserved and have been proposed to share a common function 26 . Here we use a combination of global and targeted studies to identify Orm proteins as homeostatic regulators of the first and rate-limiting step in sphingolipid biosynthesis.
Orm1/2 negatively regulate sphingolipid synthesis
We began our investigation of S. cerevisiae ORM1 and ORM2 by using a global approach to characterize gene function based on large-scale measurements of genetic interactions, termed epistatic mini-array profiles (E-MAPs) 27 . In this strategy, the function of a given gene can be inferred without a priori hypotheses by comparing the spectrum of genetic interactions resulting from mutation of that gene with interaction patterns caused by mutations in other genes of defined function. When we compared the genetic interaction profile resulting from deletion of ORM2 with those obtained for a collection of more than 1,400 yeast mutants in a study focused on ER biology (manuscript in preparation and ref. 27 ), we observed a strong anticorrelation with the interaction patterns seen for hypomorphic alleles that reduce expression of LCB1 and LCB2 (lcb1-DAmP and lcb2-DAmP 27 ), thus suggesting that ORM2 and LCB1/2 have opposing cellular roles ( Fig. 1a and Supplementary Information). We also examined the genetic interactions that result from overexpression of ORM1 or ORM2 by using the strong promoters pTDH3 and pTEF2, as it was shown that the asthma-associated polymorphisms near ORMDL3 are associated with increased expression of this gene 20, 24 . Overexpression of ORM1 or ORM2 produced a pattern of genetic interactions that was highly correlated with those seen for the lcb1-DAmP and lcb2-DAmP strains, indicating that increased Orm expression phenocopies reduced Lcb1/2 activity ( Fig. 1a ).
LCB1 and LCB2 encode serine palmitoyltransferase, an essential heterodimeric enzyme that catalyses the first and rate-limiting step in sphingolipid biosynthesis 9, 28 . The synthesis of sphingolipids begins in the ER, where two classes of lipid metabolite, long-chain bases (LCBs) and very long-chain fatty acids, are formed ( Fig. 1d ). LCBs are produced by the condensation of serine with fatty acids by serine palmitoyltransferase (Lcb1/2 in yeast and SPTLC1/2/3 in mammals), followed by Tsc10-mediated reduction 8, 9, 29 . LCBs can then be phosphorylated or N-acylated with very long-chain fatty acids to form long-chain base phosphates or ceramides, respectively, with the latter undergoing further modification to generate complex sphingolipids ( Fig. 1d ).
Thus, our E-MAP data showing a correlation between increased ORM expression and decreased LCB1/2 function implicate the Orm proteins as negative regulators of sphingolipid synthesis and highlight the reaction performed by Lcb1/2 as the possible step in the pathway at which Orm1/2 may act ( Fig. 1a, d ). We therefore examined the effects of altering Orm levels on cellular lipid composition using a mass-spectrometry-based global lipidomic technique 30 . In agreement with the genetic interaction data, overexpression of ORM1 or ORM2 resulted in changes to the lipidome, including reduced levels of LCBs and ceramides, which closely resembled those seen for the lcb2-DAmP mutant ( Fig. 1b and Supplementary Information). Conversely, cells deleted for ORM1/2 had highly increased levels of LCBs and ceramides. In principle, this accumulation of LCBs caused by deletion of ORM1/2 could result from a failure to consume these species by reaction with very long-chain fatty acids to form ceramides, as is seen when SUR4 is deleted ( Fig. 1b and ref. 30 ). However, in contrast to the sur4D strain, the increased LCB levels in the orm1D/orm2D strain are also accompanied by increased amounts of the terminal sphingolipid mannosyl-diinositolphosphorylceramide. Thus, ORM1/2 deletion causes increased flux throughout the sphingolipid pathway. This increased flux is also the primary cause of the growth defect seen in orm1D/orm2D cells, as artificially decreasing Lcb1/2 activity, either through the use of myriocin, a drug that specifically inhibits Lcb1/2 (ref. 31) , or through the lcb2-DAmP allele, significantly suppresses the growth defect caused by loss of ORM1/2 ( Fig. 1c ).
A complex with Orm1/2, Lcb1/2 and Sac1 We next explored how Orm proteins modulate sphingolipid production by identifying proteins bound by Orm1 and Orm2 in vivo. Isolation of functional 33Flag-tagged forms of Orm1 and Orm2 expressed from their endogenous loci revealed a previously uncharacterized, roughly stoichiometric complex ( Fig. 2a ). Mass spectrometry showed that this complex comprises the serine palmitoyltransferase proteins Lcb1, Lcb2 and Tsc3, in addition to the phosphoinositide phosphatase Sac1 (ref. 32) ( Supplementary Table 1 ). To characterize physical interactions among these proteins further, we used a 33Flag-tagged form of Lcb1 that is able to rescue the inviability seen upon loss of LCB1 (although this allele does exhibit mild sensitivity to myriocin). Purification of 33Flag-Lcb1 yielded the same components seen in the Orm1/2 pull-downs ( Fig. 2b) , indicating that the Orm-associated proteins are likely to exist in a single complex. Orm proteins and potentially their binding partners may also form higher-order oligomers, as we detected Orm2 coimmunoprecipitation with 33Flag-Orm1 (and vice versa) and self-association of differently tagged copies of the same Orm protein ( Fig. 2a and see later) .
The presence of Sac1 in association with Lcb1/2 suggests a new connection between this phosphoinositide phosphatase and sphingolipid biosynthesis. Deletion of SAC1 leads to increased levels of a, Genetic interaction (E-MAP) profiles were generated for strains containing ORM2 deletion, ORM1 overexpression and ORM2 overexpression alleles (orm2D, pTDH3-ORM1 and pTEF2-ORM1, and pTDH3-ORM2 and pTEF2-ORM2, respectively). Correlations between the E-MAP profiles of these strains and those of more than 1,400 other yeast mutants are shown in histograms (see Methods and Supplementary Information). b, Lipids were extracted from the indicated strains and analysed using a global mass spectrometry approach 30 . Amounts of the indicated metabolites are shown relative to wild type (WT; average 6 s.d., n 5 4; see Methods and Supplementary Information). c, Logarithmic-phase growth rates for the indicated strains were measured in standard media (YEPD) or media supplemented with myriocin at 150 ng ml 21 . Growth rates (average 6 s.d., n $ 3) are shown normalized to wild type; asterisks denote statistical significance (P , 0.05). d, Schematic of the sphingolipid biosynthesis pathway in S. cerevisiae, with selected metabolites and genes indicated. FA-CoA, fatty acid co-enzyme A; LCB-Ps, long-chain base phosphates; IPC, inositolphosphorylceramide; MIPC, mannosylinositolphosphorylceramide; MIP 2 C, mannosyl-diinositolphosphorylceramide; VLCFA-CoA, very long-chain fatty acid co-enzyme A.
LCBs ( Supplementary Fig. 1a and ref. 33 ) and resistance to the Lcb1/2 inhibitor myriocin ( Supplementary Fig. 1b ). This resistance was also seen in cells expressing the sac1-8 (ref. 34 ) catalytically inactive mutant of SAC1. Additionally, we found that Sac1 and Orm1/2 bind independently to Lcb1/2 ( Fig. 2b) and that SAC1 and ORM1/2 deletions exhibit synthetic lethality ( Supplementary Fig. 1c ). These findings together suggest that Sac1 modulates serine palmitoyltransferase activity directly, but in a mode distinct from Orm1/2. Finally, we showed that the functional complex between Orm proteins and serine palmitoyltransferase is conserved in human cells. Immunoprecipitations from HEK293T cells expressing 33Flagtagged ORMDL3 led to a prominent SPTLC1 band detected by western blot (Fig. 3a ). Furthermore, we found that simultaneous knockdown by RNA interference of ORMDL1/2/3 in HeLa cells causes an approximately threefold increase in ceramide levels (Fig. 3b , Supplementary Fig. 2 and Supplementary Information).
Together, these results establish that Orm proteins are components of a novel and conserved protein complex, which we term the SPOTS complex (serine palmitoyltransferase, Orm1/2, Tsc3, and Sac1). Additionally, our data indicate that Orm1/2 negatively regulate sphingolipid synthesis by acting directly on Lcb1/2 (for example by altering Lcb1/2 catalytic activity, accessibility of substrates to the enzyme or its subcellular localization).
Homeostatic regulation of Orm1/2 activity Why would cells include negative regulators of serine palmitoyltransferase, Orm1/2, as core components of this essential enzyme complex? This seemingly paradoxical arrangement prompted us to investigate whether Orm-mediated inhibition of LCB production might be regulated in response to changes in the cellular need for sphingolipid synthesis. We therefore examined how ORM1/2 deletion affects sensitivity to the Lcb1/2 inhibitor myriocin. Growth in the presence of myriocin is strongly dependent on the cellular capacity for LCB production, as the lcb2-DAmP strain is highly sensitive to myriocin (Fig. 4a ); in addition, SAC1 deletion, which leads to increased LCB levels, confers myriocin resistance (Fig. 4a) . Thus, naively, we might expect deletion of ORM1/2 also to confer pronounced resistance to this drug. However, we observed that wildtype and orm1D/orm2D strains exhibit comparable growth in the presence of myriocin (Fig. 4a ). Thus, loss of ORM1/2 strongly affects cell growth under standard conditions but has little apparent effect when sphingolipid synthesis is disrupted, suggesting that Orm1/2 may be inactivated in response to myriocin treatment.
To investigate this possibility further, we compared the effects of myriocin on the LCB levels of wild-type and orm1D/orm2D strains. As described earlier, the ORM1/2 deletion strain exhibits highly increased LCB levels in the absence of myriocin. However, with increasing doses of myriocin, LCB levels in the orm1D/orm2D strain decrease strongly and approximately converge with those of the wildtype strain (Fig. 4b) , supporting our growth data indicating that Orm1/2 may be inactivated in response to myriocin treatment (Fig. 4a) . Interestingly, we also found that wild-type cells maintain roughly constant LCB levels even at intermediate concentrations of myriocin (up to about 40 ng ml 21 ). This robustness is not due to a failure of myriocin to affect Lcb1/2 at these concentrations, as LCB levels in the orm1D/orm2D strain are reduced strongly by the same drug concentrations ( Fig. 4b ; for further evidence see Fig. 4d ). Rather, these results indicate that progressive inactivation of Orm1/2 may provide cells with a homeostatic mechanism to maintain nearly constant sphingolipid output in the face of increasing Lcb1/2 inhibition. Consistent with this hypothesis, LCB levels in the wild-type strain begin to decline only at myriocin concentrations where Orm-mediated inhibition of LCB synthesis appears to be fully relieved, as evidenced by convergence of wild-type and orm1D/ orm2D LCB levels (Fig. 4b) .
Orm1/2 regulation by phosphorylation
We next investigated the mechanism by which Orm1/2 activity might be decreased in response to myriocin treatment. Growth in myriocin did not alter Orm1/2 expression levels ( Fig. 4c and Supplementary  Fig. 7 ) or abolish their ability to interact with Lcb1/2 and Sac1 (Supplementary Fig. 3 ). However, we observed a notable reduction in localization of green fluorescent protein (GFP)-Orm2 to the cortical but not perinuclear ER after treatment with myriocin (Supplementary Fig. 4 ), raising the possibility that changes in subcellular localization contribute to regulation of SPOTS complex activity. We also found a strong reduction in Orm protein co-immunoprecipitation in cells treated with myriocin ( Fig. 4c) , both for Orm1-Orm2 interaction and for self-association of Orm1 and of Orm2. A weak reduction in Orm-Lcb1 binding was also observed in response to myriocin (Fig. 4c) . These findings suggest a model in which Orm-Lcb1/2 sub-complexes can self-associate into higher-order oligomers in a a, Colloidal-stained gels are shown for proteins eluted after affinity purifications from strains expressing 33Flag-Orm1 or 33Flag-Orm2, or from an untagged control strain. Immunoprecipitated proteins were identified by mass spectrometry (Supplementary Table 1 ; asterisk indicates the partly obscured protein Tsc3, whose presence was confirmed by mass spectrometry). b, Affinity purifications of 33Flag-Lcb1 from wild-type, sac1D and orm1D/orm2D strains were performed as in a. Asterisks indicate bands that are lost in deletion backgrounds.
manner that is inhibited in response to disruptions to sphingolipid synthesis.
We also detected in our Orm1/2 co-immunoprecipitations a slight shift in the electrophoretic mobility of Orm1 isolated from myriocintreated cells, indicating that Orm proteins may be post-translationally modified (see Fig. 4c , Flag-Orm1 and haemagglutinin (HA)-Orm1 inputs). Analysis of 33Flag-Orm1 and 33Flag-Orm2 in SDSpolyacrylamide gel electrophoresis (SDS-PAGE) gels that incorporated a phosphate-binding agent to improve the separation of phosphorylated species 35 resolved multiple phosphorylated forms for both Orm1 and Orm2 that collapsed to faster-migrating species upon phosphatase treatment (Fig. 4d ). Importantly, growth in myriocin induced a dose-dependent shift to more highly phosphorylated forms, and this response occurred over the same concentrations of myriocin that led to homeostatic inactivation of Orm1/2, as determined by measurements of LCBs (compare Fig. 4b and 4d ). We also observed increased Orm1/2 phosphorylation after shutting off expression of downstream sphingolipid synthetic enzymes such as Tsc10 or Lag1 (in a lac1D background; Supplementary Fig. 5 ), further indicating that phosphorylation of Orm proteins is a homeostatic response to disruption of sphingolipid production (see Fig. 5c ). Finally, we did not observe substantial changes in Orm1/2 phosphorylation upon shutting off expression of AUR1 or CSG2 ( Supplementary Fig. 5 ), thus providing preliminary evidence that a metabolite upstream of these enzymes, such as ceramide, is an intermediate whose levels are sensed to regulate Orm1/2 activity.
To test our phosphorylation-mediated feedback model directly, we identified residues of Orm1 and Orm2 that are phosphorylated. Through a combination of targeted mutagenesis and mass spectrometry, we found several sites of Orm1 and Orm2 phosphorylation in the amino-terminal regions of these proteins (Fig. 5a and Supplementary Fig. 6 ). Importantly, mutation of these sites to alanine blocks formation of the slower-migrating phosphorylated species seen in phosphate-affinity gels (Fig. 5a ). This loss of phosphorylation is unlikely to be due to these mutations resulting in non-functional Orm proteins, as the phospho-mutants are expressed at levels comparable to wild type and rescue the slow growth of the orm1D/orm2D strain ( Supplementary Fig. 7 and data not shown). Furthermore, immunoprecipitations of phospho-mutant Orm1 and Orm2 revealed that these proteins not only maintain the ability to interact with Lcb1 and each other, but that blocking phosphorylation prevents the change in higher-order assembly of the SPOTS complex normally seen in response to myriocin (Fig. 5b ). Thus Orm1/2 phosphorylation appears to be the event that triggers dynamic regulation of SPOTS complex oligomerization.
We next investigated the in vivo role of Orm1/2 phosphorylation. Consistent with a basal level of Orm1/2 phosphorylation that is important for steady-state LCB production, we observed a substantial (twofold) reduction in LCB levels in the ORM1/2 phospho-mutant strain under standard growth conditions (Fig. 5d ). Furthermore, we found that this strain is highly sensitive to treatment with myriocin ( Fig. 5e ). This result therefore confirms a key prediction of our homeostatic model and indicates that although cells may possess additional mechanisms to regulate sphingolipid biosynthesis, such pathways cannot compensate for disruption of the critical feedback control provided by Orm1/2. Thus, Orm proteins are dynamic negative regulators of serine palmitoyltransferase, whose inhibitory activity is dependent on adequate levels of downstream sphingolipids (Fig. 5c ).
Discussion
Our studies identify Orm proteins as homeostatic regulators of sphingolipid metabolism and demonstrate that alteration of these controls leads to misregulation of sphingolipid production (Fig. 5c ). Specifically, loss of the Orm1/2-mediated brake on serine palmitoyltransferase activity results in toxic accumulation of sphingolipids, whereas mutations that prevent this brake from being removed render cells unable to survive disruptions to sphingolipid synthesis.
A phosphorylation-based feedback loop provides a mechanistic basis for homeostatic regulation of sphingolipid production and exhibits several features that make it well suited to control sphingolipid levels precisely. First, phosphorylation of a direct regulator of serine palmitoyltransferase may enable cells to respond rapidly to changing environments. Second, Orm1/2 exhibit partial phosphorylation under standard growth conditions, which may position the c, Native immunoprecipitations of 33Flag-tagged Orm1 and Orm2 were performed from strains grown in standard media or media supplemented with 150 ng ml 21 myriocin, and analysed by western blot. The indicated strains also expressed 33HA-Orm1/2 from their endogenous loci (diploid strains were used to examine self-association of Orm1 and Orm2). d, Lysates were prepared from yeast expressing 33Flag-Orm1/2 after growth in media containing the indicated concentrations of myriocin. Western blots show phosphorylated forms of 33Flag-Orm1 (P-Orm1) and 33Flag-Orm2 (P-Orm2) after separation on phosphate-affinity gels 35 . An immunoprecipitated (IP) sample treated with calf intestine phosphatase (CIP) shows the position of unphosphorylated Orm1/2.
Orm1/2-based sphingolipid rheostat for maximal sensitivity to changes in lipid metabolism. Furthermore, multi-site phosphorylation of Orm1 and Orm2 has the potential to generate several distinct and stable phospho-states, which may provide cells with a graded mechanism to adjust lipid production finely to match cellular needs. Finally, several phosphorylation sites may also render Orm1/2 responsive to multiple physiological or metabolic cues. Our identification of the SPOTS complex reveals a new mechanism by which cells may be able to coordinate a variety of important secretory pathway processes. Although a link between sphingolipids and phosphoinositides has been appreciated for some time 29, 33, 36 , we provide evidence that the phosphoinositide phosphatase Sac1 directly modulates sphingolipid metabolism, as it is associated physically with serine palmitoyltransferase. These results are of particular interest given the role of phosphoinositides, including the Sac1 substrate phosphatidylinositol-4-phosphate, in the trafficking of both proteins and sphingolipids from the ER and Golgi apparatus 10, 11, 32 . Additionally, changes in Sac1 localization from the ER to the Golgi have been shown in both yeast and mammals to regulate protein flux through the secretory pathway in response to nutrient levels 37 . We therefore suggest that the SPOTS complex may represent a dynamic coordinating centre that couples changes in sphingolipid and nutrient levels to the activity and localization of key enzymes of lipid metabolism and trafficking. This model is consistent with our finding that Orm proteins self-associate in a regulated fashion and with evidence that mammalian serine palmitoyltransferase is part of a high-molecularmass complex 38 .
Finally, our characterization of ORM gene function provides a framework for investigating whether alterations in ORMDL3 activity and sphingolipid metabolism play a role in the pathogenesis of asthma. Several studies support a role for sphingolipids such as ceramide and sphingosine-1-phosphate in asthma-associated inflammatory processes, including mast-cell degranulation, airway hyper-responsiveness and immune-cell trafficking [39] [40] [41] [42] [43] . Our findings now link this growing body of evidence to the identification of single nucleotide polymorphisms near ORMDL3 that are associated with childhood asthma 20 . Specifically, our observation that altered Orm levels strongly impact sphingolipid metabolism raises the testable hypothesis that misregulation of sphingolipids may have a direct and causative role in the development of asthma. A broader potential role for sphingolipids in inflammatory disease is also suggested by reports that single nucleotide polymorphisms near ORMDL3 are associated with Crohn's disease 44 , type I diabetes 45 and primary biliary cirrhosis 46 . Finally, the existence of a rich set of pharmacological tools targeting the sphingolipid pathway 31 raises the possibility of therapeutic intervention to counteract the potential effects of changes in ORMDL3 activity.
METHODS SUMMARY
Phosphorylation analysis by phosphate-affinity SDS-PAGE. Lysates for phosphorylation analysis were prepared by pelleting and immediately resuspending logarithmically growing yeast in SDS lysis buffer (50 mM Tris-Cl, pH 6.8, 2% SDS, 10% glycerol) with protease inhibitors (Complete EDTA-free Protease Inhibitor Tablets; Roche) at 65 uC. SDS-PAGE gels with phosphate affinity reagent 35 (synthesized according to standard synthetic procedures) were prepared with a 7.5% acrylamide resolving gel with 50 mM MnCl 2 and 25 mM phosphate affinity reagent (375 mM Tris, pH 8.8, 0.1% SDS). Gels were run at 70 V for 2.5 h, rinsed twice for 5 min in transfer buffer with 1 mM EDTA and rinsed twice more for 5 min in transfer buffer without EDTA before transfer to nitrocellulose membranes. Western blots. Proteins were transferred from SDS-PAGE gels to nitrocellulose membranes and probed for proteins of interest by using standard western blot procedures. Antibodies used were as follows: rabbit anti-Flag (Sigma Aldrich), mouse anti-Flag (M2; Sigma Aldrich), mouse anti-HA antibodies 12CA5 (Roche) and HA.11 (Covance), mouse anti-yPgk1 (Molecular Probes), rabbit anti-yLcb1 (raised against peptide antigen SYIKKSHHDDPYRTTC; Abgent), mouse anti-hSPTLC1 (Becton Dickinson) and rabbit anti-ORMDL1/2/3 (raised against peptide antigen KGTPFETPDQGKARLC; Abgent). Western blots were scanned using an Odyssey fluorescent scanner (Li-Cor Biosciences).
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. sphingolipid homeostasis. a, Lysates were prepared from strains expressing wild-type or phospho-site mutant 33Flag-Orm1 or 33Flag-Orm2 after growth in standard media or media supplemented with 150 ng ml 21 myriocin. Western blots are shown after protein separation on phosphateaffinity gels. Residues mutated to alanine in the indicated phospho-mutants are highlighted in red below. b, Native immunoprecipitations of 33Flagtagged wild-type or phospho-mutant Orm1 and Orm2 were performed from strains expressing wild-type or phospho-mutant 33HA-Orm1/2 after growth in standard media or media supplemented with 100 ng ml 21 myriocin. Western blots were analysed as in Fig. 4c . c, Model for homeostatic regulation of Orm1/2, in which Orm proteins act as negative regulators of serine palmitoyltransferase (Lcb1, Lcb2 and Tsc3), whose inhibitory activity is dependent on levels of downstream sphingolipids. See Fig. 1d for abbreviations used. d, LCBs were extracted and analysed from wild-type and 33Flag-tagged ORM1/2 double phospho-mutant strains grown in standard media. Data were analysed as in Fig. 4b (average 6 s.d., n 5 3). e, Serial dilutions of wild-type, ORM1/2 deletion and 33Flag-tagged ORM1/2 double-phospho-mutant strains were spotted on plates with 0 or 280 ng ml 21 myriocin and imaged after growth for 24-36 h.
